Aldeyra Therapeutics (ALDX) Q4 2022 Earnings Call Summary

1Key Financial Results and Metrics

Cash Position: As of December 31, 2022, Aldeyra reported cash, cash equivalents, and marketable securities totaling $174.3 million. This is expected to fund operations into the second half of 2024.

Net Loss: The net loss for 2022 was $62.0 million ($1.06 per share), compared to a net loss of $57.8 million ($1.07 per share) in 2021.

Operating Expenses: Total operating expenses increased to $62.7 million from $56.2 million in 2021, driven by higher R&D and administrative costs.

2Strategic Updates and Business Highlights

FDA Submissions: Aldeyra achieved two significant milestones with the acceptance of new drug applications (NDAs) for:

Reproxalap: for dry eye disease.

ADX-2191: for primary vitreoretinal lymphoma, which received priority review status.

Clinical Trials: The company is advancing its RASP modulation platform with ongoing Phase 2 trials for ADX-629, targeting various systemic diseases, and plans to initiate trials for ADX-246 and ADX-248 in 2023.

Commercialization Plans: Aldeyra is preparing for the potential commercialization of Reproxalap and ADX-2191, with a focus on internal launch strategies if partnerships are not secured.

3Forward Guidance and Outlook

PDUFA Dates:

ADX-2191: has a PDUFA date set for June 21, 2023.

Reproxalap: has a PDUFA date of November 23, 2023.

Clinical Results: Top-line results from ongoing clinical trials for ADX-629 and ADX-2191 are expected in the first half of 2023.

Market Potential: The addressable market for Reproxalap in dry eye disease is estimated at $23 billion in the U.S.

4Bad News, Challenges, or Points of Concern

Increased Losses: The increase in net loss and operating expenses raises concerns about the sustainability of operations without additional funding or revenue generation.

Regulatory Risks: While the acceptance of NDAs reduces some regulatory risks, the outcomes of the FDA reviews remain uncertain.

Market Competition: Aldeyra faces competition in the dry eye and retinal disease markets, and the success of Reproxalap and ADX-2191 will depend on their differentiation from existing therapies.

5Notable Q&A Insights

Side Effect Profile: Dr. Brady highlighted that ADX-629 has shown a favorable safety profile with no serious adverse events reported, positioning it as a potentially safer alternative to existing treatments.

Partnering Discussions: There is robust interest in partnering for Reproxalap, with discussions ongoing, particularly as the NDA submission is viewed as comprehensive.

Differentiation in Indications: The company is exploring multiple indications for its RASP modulators, with ADX-246 expected to target similar diseases as ADX-629 but with potentially improved pharmacokinetics.

Visual Acuity Data: The improvement in visual acuity with Reproxalap was noted as statistically significant and could serve as a key differentiator in the competitive landscape for dry eye treatments. Overall, Aldeyra Therapeutics is positioned for a pivotal year in 2023, with critical regulatory milestones and a promising pipeline, despite facing challenges related to financial sustainability and market competition.